201 related articles for article (PubMed ID: 10219982)
41. Potent and long-acting corticotropin releasing factor (CRF) receptor 2 selective peptide competitive antagonists.
Rivier J; Gulyas J; Kirby D; Low W; Perrin MH; Kunitake K; DiGruccio M; Vaughan J; Reubi JC; Waser B; Koerber SC; Martinez V; Wang L; Taché Y; Vale W
J Med Chem; 2002 Oct; 45(21):4737-47. PubMed ID: 12361401
[TBL] [Abstract][Full Text] [Related]
42. 125I-Antisauvagine-30: a novel and specific high-affinity radioligand for the characterization of corticotropin-releasing factor type 2 receptors.
Higelin J; Py-Lang G; Paternoster C; Ellis GJ; Patel A; Dautzenberg FM
Neuropharmacology; 2001; 40(1):114-22. PubMed ID: 11077077
[TBL] [Abstract][Full Text] [Related]
43. Urocortin is the principal ligand for the corticotrophin-releasing factor binding protein in the ovine brain with no evidence for a sauvagine-like peptide.
Baigent SM; Lowry PJ
J Mol Endocrinol; 2000 Feb; 24(1):53-63. PubMed ID: 10656997
[TBL] [Abstract][Full Text] [Related]
44. Isolation and pharmacological characterization of two functional splice variants of corticotropin-releasing factor type 2 receptor from Tupaia belangeri.
Palchaudhuri MR; Hauger RL; Wille S; Fuchs E; Dautzenberg FM
J Neuroendocrinol; 1999 Jun; 11(6):419-28. PubMed ID: 10336722
[TBL] [Abstract][Full Text] [Related]
45. Monkey corticotropin-releasing factor1 receptor: Complementary DNA cloning and pharmacological characterization.
Oshida Y; Ikeda Y; Chaki S; Okuyama S
Life Sci; 2004 Feb; 74(15):1911-24. PubMed ID: 14761672
[TBL] [Abstract][Full Text] [Related]
46. Pharmacological characterization of recombinant rat corticotropin releasing factor binding protein using different sauvagine analogs.
Jahn O; Eckart K; Sydow S; Hofmann BA; Spiess J
Peptides; 2001 Jan; 22(1):47-56. PubMed ID: 11179597
[TBL] [Abstract][Full Text] [Related]
47. The brain corticotropin-releasing factor (CRF) receptor is of lower apparent molecular weight than the CRF receptor in anterior pituitary. Evidence from chemical cross-linking studies.
Grigoriadis DE; De Souza EB
J Biol Chem; 1988 Aug; 263(22):10927-31. PubMed ID: 2839512
[TBL] [Abstract][Full Text] [Related]
48. The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain.
Lawrence AJ; Krstew EV; Dautzenberg FM; Rühmann A
Br J Pharmacol; 2002 Jul; 136(6):896-904. PubMed ID: 12110614
[TBL] [Abstract][Full Text] [Related]
49. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
[TBL] [Abstract][Full Text] [Related]
50. Pharmacological characterisation of the recombinant human CRF binding protein using a simple assay.
Ardati A; Gottowik J; Henriot S; Clerc RG; Kilpatrick GJ
J Neurosci Methods; 1998 Mar; 80(1):99-105. PubMed ID: 9606055
[TBL] [Abstract][Full Text] [Related]
51. Modulation of Ca2+ influx by corticotropin-releasing factor (CRF) family of peptides via CRF receptors in rat pancreatic beta-cells.
Kageyama K; Kimura R; Suga S; Ogawa Y; Suda T; Wakui M
Peptides; 2006 Jul; 27(7):1814-9. PubMed ID: 16513211
[TBL] [Abstract][Full Text] [Related]
52. Juxtamembrane region of the amino terminus of the corticotropin releasing factor receptor type 1 is important for ligand interaction.
Assil IQ; Qi LJ; Arai M; Shomali M; Abou-Samra AB
Biochemistry; 2001 Feb; 40(5):1187-95. PubMed ID: 11170443
[TBL] [Abstract][Full Text] [Related]
53. Mechanism of corticotropin-releasing factor type I receptor regulation by nonpeptide antagonists.
Hoare SR; Sullivan SK; Ling N; Crowe PD; Grigoriadis DE
Mol Pharmacol; 2003 Mar; 63(3):751-65. PubMed ID: 12606786
[TBL] [Abstract][Full Text] [Related]
54. Comparison of an agonist, urocortin, and an antagonist, astressin, as radioligands for characterization of corticotropin-releasing factor receptors.
Perrin MH; Sutton SW; Cervini LA; Rivier JE; Vale WW
J Pharmacol Exp Ther; 1999 Feb; 288(2):729-34. PubMed ID: 9918582
[TBL] [Abstract][Full Text] [Related]
55. Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors.
Liaw CW; Grigoriadis DE; Lorang MT; De Souza EB; Maki RA
Mol Endocrinol; 1997 Dec; 11(13):2048-53. PubMed ID: 9415408
[TBL] [Abstract][Full Text] [Related]
56. The alternatively spliced type II corticotropin-releasing factor receptor, stably expressed in LLCPK-1 cells, is not well coupled to the G protein(s).
Nabhan C; Xiong Y; Xie LY; Abou-Samra AB
Biochem Biophys Res Commun; 1995 Jul; 212(3):1015-21. PubMed ID: 7626087
[TBL] [Abstract][Full Text] [Related]
57. An artificial peptide with corticotropin-releasing factor receptor-2 (CRF-R2) selective properties: the role of primary structure in the induction of signal transduction pathways.
Tellam DJ; Smart D; Qian X; Lovejoy DA
J Pept Res; 2002 Oct; 60(4):215-22. PubMed ID: 12366528
[TBL] [Abstract][Full Text] [Related]
58. Localization of novel corticotropin-releasing factor receptor (CRF2) mRNA expression to specific subcortical nuclei in rat brain: comparison with CRF1 receptor mRNA expression.
Chalmers DT; Lovenberg TW; De Souza EB
J Neurosci; 1995 Oct; 15(10):6340-50. PubMed ID: 7472399
[TBL] [Abstract][Full Text] [Related]
59. Cortagine, a specific agonist of corticotropin-releasing factor receptor subtype 1, is anxiogenic and antidepressive in the mouse model.
Tezval H; Jahn O; Todorovic C; Sasse A; Eckart K; Spiess J
Proc Natl Acad Sci U S A; 2004 Jun; 101(25):9468-73. PubMed ID: 15192151
[TBL] [Abstract][Full Text] [Related]
60. Achieving signalling selectivity of ligands for the corticotropin-releasing factor type 1 receptor by modifying the agonist's signalling domain.
Beyermann M; Heinrich N; Fechner K; Furkert J; Zhang W; Kraetke O; Bienert M; Berger H
Br J Pharmacol; 2007 Jul; 151(6):851-9. PubMed ID: 17533422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
